Semaglutide (Rybelsus®). HTA ID: 20011

Assessment Status Assessment Process Complete
HTA ID 20011
Drug Semaglutide
Brand Rybelsus®
Indication For the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise: (a) as monotherapy when metformin is considered inappropriate due to intolerance or contraindications. (b) in combination with other medicinal products for the treatment of diabetes.
Assessment Process
Rapid review commissioned 02/03/2020
Rapid review completed 30/03/2020
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost-effectiveness of oral semaglutide (Rybelsus®) compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 07/04/2020
Pre-submission consultation with Applicant 16/06/2020
Full submission received from Applicant 18/11/2020
Preliminary review sent to Applicant 21/12/2020
NCPE assessment re-commenced 29/01/2021
NCPE assessment re-commenced 11/02/2021
NCPE assessment completed 17/02/2021
NCPE assessment outcome The NCPE recommends that oral semaglutide should not be considered for reimbursement unless cost-effectiveness can be improved relative to existing therapy*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.